INT161109

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 0.18
Pain Relevance 4.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Avp) extracellular space (Avp) extracellular region (Avp)
cytoplasm (Chkb) response to stress (Avp) signal transducer activity (Avp)
Avp (Rattus norvegicus)
Chkb (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Enkephalin 12 100.00 Very High Very High Very High
Raphe magnus 16 99.66 Very High Very High Very High
Dopamine 2 97.70 Very High Very High Very High
Glutamate 2 97.50 Very High Very High Very High
Neurotransmitter 4 95.52 Very High Very High Very High
antinociception 10 94.44 High High
Serotonin 4 93.78 High High
antagonist 6 91.40 High High
Pain 4 90.84 High High
narcan 2 90.80 High High
Disease Link Frequency Relevance Heat
Pain 2 90.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results showed that (1) in the NRM perfuse liquid, pain stimulation could increase the concentrations of AVP, leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek), beta-endorphin (beta-Ep), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), but not change the concentrations of dynorphinA(1-13) (DynA(1-13)), oxytocin, achetylcholine, choline, gamma-aminobutyric acid, glutamate, dopamine, 3,4-dihydroxyphenylacetic acid, homovanilic acid, norepinephrine and epinephrine; (2) in the NRM perfuse liquid, AVP increased the concentrations of L-Ek, M-Ek, beta-Ep, DynA(1-13), 5-HT and 5-HIAA, but did not change the concentrations of oxytocin and the other studied neurotransmitters; (3) AVP antinociception in the NRM was attenuated by cypoheptadine (a 5-HT-receptor antagonist) or naloxone (an opiate receptor antagonist), but was not influenced by the other studied receptor antagonists.
AVP Positive_regulation (increased) of M-Ek associated with pain, dopamine, narcan, enkephalin, raphe magnus, antinociception, glutamate, neurotransmitter, antagonist, opiate and serotonin
1) Confidence 0.12 Published 2009 Journal Peptides Section Abstract Doc Link 19540433 Disease Relevance 0.09 Pain Relevance 2.10
The results showed that (1) in the NRM perfuse liquid, pain stimulation could increase the concentrations of AVP, leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek), beta-endorphin (beta-Ep), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), but not change the concentrations of dynorphinA(1-13) (DynA(1-13)), oxytocin, achetylcholine, choline, gamma-aminobutyric acid, glutamate, dopamine, 3,4-dihydroxyphenylacetic acid, homovanilic acid, norepinephrine and epinephrine; (2) in the NRM perfuse liquid, AVP increased the concentrations of L-Ek, M-Ek, beta-Ep, DynA(1-13), 5-HT and 5-HIAA, but did not change the concentrations of oxytocin and the other studied neurotransmitters; (3) AVP antinociception in the NRM was attenuated by cypoheptadine (a 5-HT-receptor antagonist) or naloxone (an opiate receptor antagonist), but was not influenced by the other studied receptor antagonists.
AVP Positive_regulation (increased) of L-Ek associated with pain, dopamine, narcan, enkephalin, raphe magnus, antinociception, glutamate, neurotransmitter, antagonist, opiate and serotonin
2) Confidence 0.05 Published 2009 Journal Peptides Section Abstract Doc Link 19540433 Disease Relevance 0.09 Pain Relevance 2.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox